Repare Therapeutics

General Information


We are a leading precision oncology company enabled by our proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Synthetic lethality, or SL, represents a clinically validated approach to drug development. We use our proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. SL arises when a deficiency in either of two genes is tolerated in cells, but simultaneous deficiencies in both genes cause cell death.

Employees: 64
Founded: 2016
Contact Information
Address 7210 Frederick-Banting, Suite 100, Montréal, Québec, Canada H4S 2A1,
Phone Number (857) 412-7018
Web Address
View Prospectus: Repare Therapeutics
Financial Information
Market Cap $700.4mil
Revenues $0 mil (last 12 months)
Net Income $-34.98 mil (last 12 months)
IPO Profile
Symbol RPTX
Exchange NASDAQ
Shares (millions): 11.0
Price range $20.00 - $20.00
Est. $ Volume $220.0 mil
Manager / Joint Managers Morgan Stanley/ Goldman Sachs/ Cowen and Company/ Piper Sandler
CO-Managers -
Expected To Trade: 6/19/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change